Back HCV Treatment

HCV Treatment

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17

alt

HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs

Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during 3 years of follow-up, researchers reported at the 25th Harm Reduction International Conference this week in Montreal.

alt

Read more:

EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates

Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.

alt

Read more:

EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis

A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.

alt

Read more: